ArticleHeart (British Cardiac Society)2002
Low prevalence of lipid lowering drug use in older men with established coronary heart disease.
Article in Heart (British Cardiac Society), 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 76 citations in OpenAlex.
- Hyperlipidemias in elderly patients: results from the Berlin Aging Study II (BASEII), a cross-sectional study.Lipids in health and disease · 2020Trial
- Time trends in statin use and incidence of recurrent cardiovascular events in secondary prevention between 1999 and 2013: a registry-based study.BMC cardiovascular disorders · 2018Article
- Primary prevention of cardiovascular disease with statins in the elderly.Current atherosclerosis reports · 2014Review
- Missed opportunities in prevention of cardiovascular disease in primary care: a cross-sectional study.The British journal of general practice : the journal of the Royal College of General Practitioners · 2014Article
- Statins in the primary prevention of cardiovascular disease.Nature reviews. Cardiology · 2013 · on this mapReview
- Impact of age and sex on primary preventive treatment for cardiovascular disease in the West Midlands, UK: cross sectional study.BMJ (Clinical research ed.) · 2012Article
- Clinical utility of rosuvastatin and other statins for cardiovascular risk reduction among the elderly.Clinical interventions in aging · 2011Review
- Computerized history-taking as a tool to manage dyslipidemia.Vascular health and risk management · 2010Article
- Variability in the prescription of cardiovascular medications in older patients: correlates and potential explanations.Drugs & aging · 2009Review
- Missed opportunities for secondary prevention of cerebrovascular disease in elderly British men from 1999 to 2005: a population-based study.Journal of public health (Oxford, England) · 2007Article
- How equitable are GP practice prescribing rates for statins?: an ecological study in four primary care trusts in North West England.International journal for equity in health · 2007Article
- Prevalence, incidence, primary care burden and medical treatment of angina in Scotland: age, sex and socioeconomic disparities: a population-based study.Heart (British Cardiac Society) · 2006Article
- Overcoming 'ageism' bias in the treatment of hypercholesterolaemia : a review of safety issues with statins in the elderly.Drug safety · 2006Review
- Secondary prevention of coronary heart disease in older British men: extent of inequalities before and after implementation of the National Service Framework.Journal of public health (Oxford, England) · 2005Article
- National trends in statin use by coronary heart disease risk category.PLoS medicine · 2005Article
- Coronary heart disease prevention in clinical practice: are patients with diabetes special? Evidence from two studies of older men and women.Heart (British Cardiac Society) · 2005Article
- Exploring the equity of GP practice prescribing rates for selected coronary heart disease drugs: a multiple regression analysis with proxies of healthcare need.International journal for equity in health · 2005Article
- High prevalence and undertreatment of hypercholesterolaemia in participants in a public stroke prevention programme in austria.Clinical drug investigation · 2005Article
- Are GP practice prescribing rates for coronary heart disease drugs equitable? A cross sectional analysis in four primary care trusts in England.Journal of epidemiology and community health · 2004Article
- The use of cholesterol-lowering medications after coronary revascularization.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2003Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo determine the prevalence and correlates of lipid lowering drug use among older British men with established coronary heart disease (CHD).
designCross sectional survey within a cohort study (British regional heart study) carried out at 20 years of follow up in 1998-2000.
settingGeneral practices in 24 British towns.
participants3689 men aged 60-75 years (response rate 76%).
main outcome measuresDiagnoses of myocardial infarction and angina based on detailed review of general practice records. Lipid lowering drug use and blood cholesterol concentrations ascertained at 20 year follow up examination.
resultsAmong 286 men with definite myocardial infarction, 102 (36%) were taking a lipid lowering drug (93 (33%) a statin); among 360 men with definite angina without myocardial infarction, 84 (23%) were taking a lipid lowering drug (78 (21%) a statin). Most men with documented CHD who were not receiving a lipid lowering drug had a total cholesterol concentration of 5.0 mmol/l or more (87% of those with myocardial infarction, 82% with angina). Fewer than half of men with CHD receiving a statin had a total cholesterol concentration below 5.0 mmol/l (45% of those with myocardial infarction and 47% of those with angina). Only one third of the men taking a statin were receiving trial validated dosages. Among men with CHD, a history of revascularisation, more recent diagnosis, and younger age at diagnosis were associated with a higher probability of receiving lipid lowering drug treatment.
conclusionAmong patients with established CHD, the prevalence of lipid lowering drug use remains low and statin regimens suboptimal. Major improvements in secondary prevention are essential if the benefits of statins are to be realised.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.